Korea’s Hanmi Fine Chemical, which specializes in developing and manufacturing APIs, is launching a CDMO business. The Seoul-based company will invest about 10 billion...
17.11.2015
- US-based drugs firm Janssen Pharmaceuticals has gained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based treatments for diabetes and...
13.11.2015
- French drugmaker Sanofi has entered into two separate collaborations to develop and commercialize diabetes treatments. An agreement with US-based Lexicon Pharmaceuticals centers on...
